
AstraZeneca drug shows 42% lower death risk
Key points
- AstraZeneca (NASDAQ:AZN) received US FDA Priority Review for sonesitatug vedotin (Sone-Ve), an experimental treatment for advanced gastric, gastroesophageal junction and esophageal cancers.
- The Phase III CLARITY-Gastric01 trial showed Sone-Ve reduced the risk of death by 42%, with median overall survival reaching 10.6 months versus 6.4 months for standard treatment.
- The FDA decision is expected in the second quarter of 2027, with the potential treatment targeting patients whose tumours show at least 25% CLDN18.2 expression.
AstraZeneca (NASDAQ:AZN) received US Food and Drug Administration Priority Review for sonesitatug vedotin (Sone-Ve), an experimental cancer treatment that reduced the risk of death by 42% in a Phase III trial involving patients with advanced gastric and related cancers.
The application covers second-line and later treatment of locally advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma in patients whose tumours show CLDN18.2 expression in at least 25% of tumour cells.
"After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options," said AstraZeneca Executive Vice President of Oncology Haematology R&D Susan Galbraith.
In the CLARITY-Gastric01 trial, median overall survival reached 10.6 months with Sone-Ve, compared with 6.4 months with investigator-selected treatment, while the FDA's decision is expected in the second quarter of 2027.
The treatment received Orphan Drug Designation from the US FDA and European Commission for gastric and gastroesophageal junction cancers, while China granted it Breakthrough Designation for second-line gastric cancer treatment.
AstraZeneca estimates that approximately 60% of gastric and gastroesophageal junction cancers express CLDN18.2 in at least 25% of tumour cells, potentially expanding the eligible patient population, while regulatory applications remain under review in Europe, China and other markets.
Frequently asked questions
More from United States
SunPower records higher revenue of $65.1 million
Cato Corporation net loss deepens to $10.4 million
Arbe Robotics crosses $0.8 million in quarterly revenue
Evogene quarterly loss widens to $2.86 million
Warner Music Group posts stronger fourth-quarter revenue
Manchester United revenue hits £146.1 million


